DNAJB2-related Charcot-Marie-Tooth disease type 2: Pathomechanism insights and phenotypic spectrum widening.
Parkinson's disease
genetic and inherited disorders
neuropathology
peripheral neuropathies
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
14
02
2022
received:
26
11
2021
accepted:
09
03
2022
pubmed:
15
3
2022
medline:
15
6
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
Mutations in DNAJB2 are associated with autosomal recessive hereditary motor neuropathies/ Charcot-Marie-Tooth disease type 2 (CMT2). We describe an Italian family with CMT2 due to a homozygous DNAJB2 mutation and provide insight into the pathomechanisms. Patients with DNAJB2 mutations were characterized clinically, electrophysiologically and by means of skin biopsy. mRNA and protein levels were studied in lymphoblastoid cells (LCLs) from patients and controls. Three affected siblings were found to carry a homozygous DNAJB2 null mutation segregating with the disease. The disease manifested in the second to third decade of life. Clinical examination showed severe weakness of the thigh muscles and complete loss of movement in the foot and leg muscles. Sensation was reduced in the lower limbs. All patients had severe hearing loss and the proband also had Parkinson's disease (PD). Nerve conduction studies showed an axonal motor and sensory length-dependent polyneuropathy. DNAJB2 expression studies revealed reduced mRNA levels and the absence of the protein in the homozygous subject in both LCLs and skin biopsy. Interestingly, we detected phospho-alpha-synuclein deposits in the proband, as already seen in PD patients, and demonstrated TDP-43 accumulation in patients' skin. Our results broaden the clinical spectrum of DNAJB2-related neuropathies and provide evidence that DNAJB2 mutations should be taken into account as another causative gene of CMT2 with hearing loss and parkinsonism. The mutation likely acts through a loss-of-function mechanism, leading to toxic protein aggregation such as TDP-43. The associated parkinsonism resembles the classic PD form with the addition of abnormal accumulation of phospho-alpha-synuclein.
Sections du résumé
BACKGROUND AND PURPOSE
Mutations in DNAJB2 are associated with autosomal recessive hereditary motor neuropathies/ Charcot-Marie-Tooth disease type 2 (CMT2). We describe an Italian family with CMT2 due to a homozygous DNAJB2 mutation and provide insight into the pathomechanisms.
METHODS
Patients with DNAJB2 mutations were characterized clinically, electrophysiologically and by means of skin biopsy. mRNA and protein levels were studied in lymphoblastoid cells (LCLs) from patients and controls.
RESULTS
Three affected siblings were found to carry a homozygous DNAJB2 null mutation segregating with the disease. The disease manifested in the second to third decade of life. Clinical examination showed severe weakness of the thigh muscles and complete loss of movement in the foot and leg muscles. Sensation was reduced in the lower limbs. All patients had severe hearing loss and the proband also had Parkinson's disease (PD). Nerve conduction studies showed an axonal motor and sensory length-dependent polyneuropathy. DNAJB2 expression studies revealed reduced mRNA levels and the absence of the protein in the homozygous subject in both LCLs and skin biopsy. Interestingly, we detected phospho-alpha-synuclein deposits in the proband, as already seen in PD patients, and demonstrated TDP-43 accumulation in patients' skin.
CONCLUSIONS
Our results broaden the clinical spectrum of DNAJB2-related neuropathies and provide evidence that DNAJB2 mutations should be taken into account as another causative gene of CMT2 with hearing loss and parkinsonism. The mutation likely acts through a loss-of-function mechanism, leading to toxic protein aggregation such as TDP-43. The associated parkinsonism resembles the classic PD form with the addition of abnormal accumulation of phospho-alpha-synuclein.
Identifiants
pubmed: 35286755
doi: 10.1111/ene.15326
pmc: PMC9314055
doi:
Substances chimiques
DNA-Binding Proteins
0
DNAJB2 protein, human
0
HSP40 Heat-Shock Proteins
0
Molecular Chaperones
0
RNA, Messenger
0
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2056-2065Informations de copyright
© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Ann Neurol. 2012 Apr;71(4):509-19
pubmed: 22522442
Handb Clin Neurol. 2018;148:653-665
pubmed: 29478606
Eur J Neurol. 2021 Apr;28(4):1334-1343
pubmed: 33369814
Cell Rep. 2015 Aug 18;12(7):1169-83
pubmed: 26257172
J Mol Diagn. 2016 Mar;18(2):225-34
pubmed: 26752306
Int J Mol Sci. 2020 Feb 19;21(4):
pubmed: 32093037
J Peripher Nerv Syst. 2011 Sep;16(3):191-8
pubmed: 22003934
Nature. 1998 Apr 9;392(6676):605-8
pubmed: 9560156
Hum Mutat. 2016 Nov;37(11):1180-1189
pubmed: 27449489
Eur J Neurol. 2022 Jul;29(7):2056-2065
pubmed: 35286755
Neurology. 2014 Nov 4;83(19):1726-32
pubmed: 25274842
Am J Pathol. 2010 Jun;176(6):2901-10
pubmed: 20395441
Int J Mol Sci. 2021 Apr 13;22(8):
pubmed: 33924373
Clin Auton Res. 2019 Dec;29(6):577-585
pubmed: 30506233
J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1265-1268
pubmed: 27083531
Hum Mol Genet. 2011 Jan 1;20(1):16-27
pubmed: 20889486
J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1171-1179
pubmed: 31167812
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Neurogenetics. 2007 Nov;8(4):289-99
pubmed: 17703324
Brain. 2016 May;139(Pt 5):1417-32
pubmed: 26936937
J Peripher Nerv Syst. 2010 Sep;15(3):164-75
pubmed: 21040138
Brain. 2012 May;135(Pt 5):1412-22
pubmed: 22522939